Detalles de la búsqueda
1.
A phase Ia/Ib study of novel anti-ErbB3 monoclonal antibody, barecetamab (ISU104) in refractory solid cancers and monotherapy or in combination with cetuximab in recurrent or metastatic head and neck cancer.
Int J Cancer
; 153(8): 1501-1511, 2023 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-37357950
2.
A phase 2 multicenter study of docetaxel-PM and trastuzumab-pkrb combination therapy in recurrent or metastatic salivary gland carcinomas.
Cancer
; 129(19): 2966-2974, 2023 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37246414
3.
Characteristics of metastatic brachial plexopathy in patients with breast cancer.
Support Care Cancer
; 28(4): 1913-1918, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-31363905
4.
Loss of HER2 positivity after anti-HER2 chemotherapy in HER2-positive gastric cancer patients: results of the GASTric cancer HER2 reassessment study 3 (GASTHER3).
Gastric Cancer
; 22(3): 527-535, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30386954
5.
Clinical significance of MET gene amplification in metastatic or locally advanced gastric cancer treated with first-line fluoropyrimidine and platinum combination chemotherapy.
Chin J Cancer Res
; 31(4): 620-631, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-31564805
6.
Impact of Patient Sex on Adverse Events and Unscheduled Utilization of Medical Services in Cancer Patients Undergoing Adjuvant Chemotherapy: A Multicenter Retrospective Cohort Study.
Cancer Res Treat
; 56(2): 404-413, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37933112
7.
Detection and evaluation of signals for immune-related adverse events: a nationwide, population-based study.
Front Oncol
; 13: 1295923, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38344142
8.
Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer.
Nat Cancer
; 4(6): 844-859, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37308678
9.
Analysis of Cancer Patient Decision-Making and Health Service Utilization after Enforcement of the Life-Sustaining Treatment Decision-Making Act in Korea.
Cancer Res Treat
; 54(1): 20-29, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33848413
10.
A Phase II Study to Compare the Safety and Efficacy of Direct Oral Anticoagulants versus Subcutaneous Dalteparin for Cancer-Associated Venous Thromboembolism in Patients with Advanced Upper Gastrointestinal, Hepatobiliary and Pancreatic Cancer: PRIORITY.
Cancers (Basel)
; 14(3)2022 Jan 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-35158827
11.
Functional Impairments in the Mental Health, Depression and Anxiety Related to the Viral Epidemic, and Disruption in Healthcare Service Utilization among Cancer Patients in the COVID-19 Pandemic Era.
Cancer Res Treat
; 54(3): 671-679, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34583461
12.
Integrin αvß3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non-Small Cell Lung Cancer.
Cancer Res Treat
; 54(3): 767-781, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34607394
13.
The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study.
Cancer Med
; 11(3): 705-714, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34889062
14.
Comparison of Sinusoidal Obstruction Syndrome in Gastric Cancer Patients Receiving S-1/oxaliplatin Versus Capecitabine/oxaliplatin.
Anticancer Res
; 41(1): 391-402, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-33419836
15.
Awareness of Doctors' Shared Decision-Making in Life-Sustaining Care Decisions.
J Hosp Palliat Care
; 24(4): 204-213, 2021 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37674642
16.
Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia.
Front Oncol
; 11: 766888, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34926269
17.
Rivaroxaban Versus Low-molecular-weight Heparin for Venous Thromboembolism in Advanced Upper Gastrointestinal Tract and Hepatopancreatobiliary Cancer.
In Vivo
; 34(2): 829-837, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32111791
18.
Blockade of CCL2 expression overcomes intrinsic PD-1/PD-L1 inhibitor-resistance in transglutaminase 2-induced PD-L1 positive triple negative breast cancer.
Am J Cancer Res
; 10(9): 2878-2894, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33042623
19.
The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205.
Am J Cancer Res
; 9(3): 597-607, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-30949413
20.
Transglutaminase 2 induces intrinsic EGFR-TKI resistance in NSCLC harboring EGFR sensitive mutations.
Am J Cancer Res
; 9(8): 1708-1721, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31497352